U.S. drug regulators signaled on April 29 that they may COVID-19 vaccines for young children in June.
The Food and Drug Administration (FDA) said it plans to convene its expert advisory panel, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), to consider updates to the Moderna and Pfizer emergency use authorizations (EUAs).
Moderna announced Thursday it submitted an EUA for children aged 6 months to 5 years old; Pfizer is still waiting on clinical trial data after its two-shot primary regimen failed to trigger an adequate immune response in children from 6 months to 4 years of age.
The FDA is holding the dates of June 8, 21, and 22 for the meetings.
…